Nicholas Stergis, CEO of Adeona, said: “As previously announced, we are pleased to have completed our corporate name and ticker symbol change. Our primary focus is toward the continued development of new disease-modifying treatments for autoimmune and central nervous system diseases.
“This strategy and direction is evident by our recent in-licensing of oral dnaJP1 for the treatment of rheumatoid arthritis which has completed a 160-patient, double-blind, placebo-controlled Phase II clinical trial in RA patients. Oral dnaJP1 complements our existing immunology pipeline which includes, Trimesta, an oral treatment for multiple sclerosis which is currently in a 150-patient double-blind, placebo-controlled Phase IIb clinical trial is being funded by a $5 million grant.”